Abstract 1741: AlidaBio EpiPlex: A Platform for Multiplexed Detection of RNA Modifications in Clinical Samples

Abstract It is becoming increasingly appreciated that RNA modifications are widespread in development and homeostasis, regulating RNA stability and translation, and that alterations to these modifications are associated with cancer development and progression. Although 170 different RNA modifications have been identified using mass spectrometry, there is a paucity of convenient, validated tools immediately available to cancer researchers to explore these modifications using relevant clinical samples in sufficient numbers, and accurately determine their suitability for use as diagnostic or drug targets. In addition, most existing methods concentrate only on m6A, the most prevalent modification in mRNA. Alida Bio has developed an end-to-end assay platform with an integrated bioinformatics solution that detects multiple modifications in the same reaction. This platform exploits targeted, multiplexed barcoding to reveal the quantitative abundance of modified transcripts, co-localization of multiple RNA modifications to the same gene, and gene expression profiles. Alida Bio's mission is to equip translational researchers with tools that will significantly improve their understanding of gene regulation through seamless measurement of RNA modifications. Citation Format: Andrew Price, Zachary Miles, John Chevillet, Byron Purse, Richard I. Gregory, Gudrun Stengel. AlidaBio EpiPlex: A platform for multiplexed detection of RNA modifications in clinical samples [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 1741.